DND PharmaTech Inc
KOSDAQ:347850
DND PharmaTech Inc
Research & Development
DND PharmaTech Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
DND PharmaTech Inc
KOSDAQ:347850
|
Research & Development
-₩22.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Research & Development
-₩218.9B
|
CAGR 3-Years
-91%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Research & Development
-₩20.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Research & Development
-₩17.9B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Research & Development
-₩28.4B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-31%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Research & Development
-₩95.6B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
DND PharmaTech Inc
Glance View
DND PharmaTech Inc is a KR-based company operating in Biotechnology industry. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2024-05-02. DND Pharmatech Inc is a Korea-based clinical-stage biotech company mainly engaged in the research and development in medicines. The firm's product pipeline mainly focuses on indications including metabolic disease, neurodegenerative and fibrotic diseases. In addition, the Company is engaged in the research and development of therapeutic medicines used for diabetes, obesity and nonalcoholic steatohepatitis as well as others.
See Also
What is DND PharmaTech Inc's Research & Development?
Research & Development
-22.4B
KRW
Based on the financial report for Dec 31, 2024, DND PharmaTech Inc's Research & Development amounts to -22.4B KRW.
What is DND PharmaTech Inc's Research & Development growth rate?
Research & Development CAGR 1Y
-18%
Over the last year, the Research & Development growth was -18%.
